Evidence map›Paper›PMID 32825794›Full record

ArticleJournal of clinical medicine2020

Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes.

Ana Isabel López-Lazcano, Antoni Gual, Jordi Colmenero, Elsa Caballería, Anna Lligoña, Miquel Navasa, Gonzalo Crespo, Eva López, Hugo López-Pelayo

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ana Isabel López-LazcanoGrup Recerca Addicions Clínic (GRAC-GRE), Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic i Universitari de Barcelona. Universitat de Barcelona, IDIBAPS. RTA (RETICS). Villarroel, 170, 08036 Barcelona, Spain.
Antoni GualGrup Recerca Addicions Clínic (GRAC-GRE), Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic i Universitari de Barcelona. Universitat de Barcelona, IDIBAPS. RTA (RETICS). Villarroel, 170, 08036 Barcelona, Spain.
Jordi ColmeneroLiver Unit, Hospital Clínic i Universitari de Barcelona, Universitat de Barcelona, IDIBAPS. CIBERehd, Villaroel 170, 08036 Barcelona, Spain.
Elsa CaballeríaGrup Recerca Addicions Clínic (GRAC-GRE), Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic i Universitari de Barcelona. Universitat de Barcelona, IDIBAPS. RTA (RETICS). Villarroel, 170, 08036 Barcelona, Spain.
Anna LligoñaGrup Recerca Addicions Clínic (GRAC-GRE), Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic i Universitari de Barcelona. Universitat de Barcelona, IDIBAPS. RTA (RETICS). Villarroel, 170, 08036 Barcelona, Spain.
Miquel NavasaLiver Unit, Hospital Clínic i Universitari de Barcelona, Universitat de Barcelona, IDIBAPS. CIBERehd, Villaroel 170, 08036 Barcelona, Spain.
Gonzalo CrespoLiver Unit, Hospital Clínic i Universitari de Barcelona, Universitat de Barcelona, IDIBAPS. CIBERehd, Villaroel 170, 08036 Barcelona, Spain.
Eva LópezLiver Unit, Hospital Clínic i Universitari de Barcelona, Universitat de Barcelona, IDIBAPS. CIBERehd, Villaroel 170, 08036 Barcelona, Spain.
Hugo López-PelayoGrup Recerca Addicions Clínic (GRAC-GRE), Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic i Universitari de Barcelona. Universitat de Barcelona, IDIBAPS. RTA (RETICS). Villarroel, 170, 08036 Barcelona, Spain.
Universitat de Barcelona · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ES

Funding

Generalitat de Catalunya CERCA ProgrammeInstituto de Salud Carlos III JR19/00025
6 · The paper itself

Abstract

Tobacco use is more prevalent among alcohol liver disease (ALD) transplant patients and exerts harmful effects to the patient and to the graft. The aims of this study were to examine the impact of smoking status (nonsmoker, ex-smoker, active smoker) on patient survival and clinical outcomes, and to assess risk factors for active smoking before and after liver transplant (LT). An observational retrospective cohort study with 314 ALD patients undergoing LT from January 2004 to April 2016. Recipients were followed until April 2017 or death. Kaplan-Meier and Cox proportional hazards regression analyses were used to assess risk of mortality according to smoking status before LT. Smokers had a 79% higher risk of dying than those who had never smoked or quit smoking before LT. Ex-smokers had a greater survival probability (96.2%, 93.8%, 86.9%, and 83.1% at 1, 3, 5, and 10 years after LT) than active smokers until LT (96.0%, 85.6%, 80.0%, and 70.4%). Active smokers before LT with poor toxicity awareness had more than a twofold higher risk of mortality (Cox HR = 2.20, 95% CI: 1.05-4.58,

Indexed as

alcohol use disorderliver transplantrisk factorssmokingsurvival

Identifiers

PMID32825794
PMCPMC7564808
OpenAlexW3080503466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.